Breaking News

Samsung Biologics Wins $1.06B Contract

Agreement is with an undisclosed U.S.-based pharmaceutical company.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics, a contract development and manufacturing organization (CDMO), has signed a $1.06 billion manufacturing agreement with an undisclosed U.S.-based pharmaceutical company following a letter of intent (LOI) signed in June of last year. The product has not been disclosed. The contract period extends until December 31, 2030. Last June, Samsung Biologics reported plans to have its new fifth plant operational by April 2025. On June 1, the company fully completed its latest and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters